Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Stalevo approval in Parkinson’s

Executive Summary

FDA approves Orion/Novartis' Stalevo June 12 for treatment of idiopathic Parkinson's disease. One of Stalevo's indications in labeling is as substitute "for immediate release carbidopa/levodopa and entacapone (Orion/Novartis' Comtan) previously administered as individual products." Stalevo is combination of carbidopa (12.5 mg, 25 mg or 37.5 mg), levodopa (50 mg, 100 mg or 150 mg) and entacapone (200 mg). Labeling suggests easy switch from Comtan 200 mg to the corresponding strength of Stalevo with same amounts of levodopa and carbidopa...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS041972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel